

Loren H. Parsons · Friedbert Weiss · George F. Koob

Serotonin_{1B} receptor stimulation enhances dopamine-mediated reinforcement

Received: 5 February 1996/Final version: 20 June 1996

Abstract The effect of 5-HT_{1B} receptor stimulation on dopamine-mediated reinforcement in rats was investigated using intravenous self-administration of the selective dopamine uptake inhibitor GBR-12909 on an FR5 schedule of reinforcement. Pretreatment with the 5-HT_{1A/1B} receptor agonist CGS-12066B (1–10 mg/kg, IP) dose-dependently reduced the self-administration of GBR-12909 (83 µg/injection) by increasing the interval between drug injections, consistent with an enhancement of the reinforcing effects of GBR-12909. Additionally, CGS-12066B pretreatment (3 mg/kg, IP) shifted the dose-effect function for GBR-12909 self-administration to the left. Pretreatment with the selective 5-HT_{1A} receptor agonist 8-OH-DPAT (0.03–1.0 mg/kg, SC) had no significant effect on GBR-12909 self-administration (83 µg/injection), indicating that the effect of CGS-12066B is not mediated by the 5-HT_{1A} receptor. Finally, CGS-12066B pretreatment (1–10 mg/kg, IP) did not alter the self-administration of cocaine (0.03–0.5 mg/injection), suggesting that the simultaneous stimulation of multiple 5-HT receptor subtypes by the indirect 5-HT agonist properties of cocaine may mask the effect of 5-HT_{1B} receptor stimulation on DA-mediated reinforcement.

Key words 5-HT_{1B} receptors · GBR-12909 · CGS-12066B · Self-administration · 8-OH-DPAT · Cocaine

Introduction

A large body of evidence indicates that the reinforcing effects of cocaine and other psychostimulants are

dependent on the ability of these drugs to enhance dopamine (DA) neurotransmission in the mesocorticolimbic system (Roberts et al. 1977, 1980; Wise 1984; Ritz et al. 1987; Koob and Bloom 1988; Kuhar et al. 1991). However, in addition to increasing interstitial DA concentrations, psychostimulants also elevate extracellular serotonin (5-HT) and norepinephrine (NE) levels (Koe 1976), suggesting that monoaminergic systems other than DA may also contribute to the reinforcing and addictive properties of these drugs.

There is increasing evidence that both dopaminergic and serotonergic neurotransmission are involved in mediating the behavioral and neurophysiological effects of cocaine. In humans, depletion of the 5-HT precursor tryptophan attenuates both the euphorogenic and anxiogenic effects of intranasal cocaine (Aronson et al. 1995) as well as cue-induced craving for cocaine (Satel et al. 1995). In rats, the reinforcing properties of cocaine self-administration are altered by the manipulation of both the dopaminergic (Koob 1992) and serotonergic systems (Carroll et al. 1990a, b; Loh and Roberts 1990; Richardson and Roberts 1991; McGregor et al. 1993; Peltier and Schenk 1993; Spealman 1993). Moreover, repeated cocaine exposure produces cross-tolerance to the cocaine analogue WIN 35,428, a compound that like cocaine, has affinity for the 5-HT uptake transporter (Rudnik and Wall 1991). However, cocaine does not produce cross-tolerance to GBR-12909 (Katz et al. 1993), a DA reuptake inhibitor which does not have appreciable affinity for the 5-HT transporter (Heikkila and Manzino 1984; Anderson 1989). Acute cocaine exposure dramatically alters the electrophysiology of both the dopaminergic and serotonergic systems (for review see Cunningham 1995; White et al. 1995), and chronic exposure to cocaine results in pronounced decrements in both DA and 5-HT activity (for review see Cunningham 1995; Weiss et al. 1995; White et al. 1995). The simultaneous involvement of these systems in the neurophysiological effects of cocaine is demonstrated by the findings that the *combined* stimulation

L.H. Parsons (✉) · F. Weiss · G.F. Koob
Division of Psychopharmacology,
Department of Neuropharmacology,
The Scripps Research Institute, 10666 N. Torrey Pines Road,
La Jolla, CA 92037, USA

of both DA and 5-HT receptors are required to mimic the effects of cocaine on striatal gene expression (Bhat and Baraban 1993) and nucleus accumbens (NAcc) electrophysiology (White et al. 1993). Together, these findings suggest that in addition to DA, 5-HT is also involved in mediating or modulating the behavioral and neurophysiological effects of cocaine.

Based on anatomical and pharmacological evidence, it may be hypothesized that serotonergic neurotransmission affects the reinforcing properties of cocaine by modulating dopaminergic activity. For example, a dense serotonergic innervation is found in the ventral tegmental area (VTA) (Conrad et al. 1974; Azmitia and Segal 1978; Phelix and Broderick 1995), and these 5-HT neurons have been shown to form direct synaptic contact on DA cells bodies in this region (Parent et al. 1981; Hervé et al. 1987). These DA cells project to the NAcc and are implicated in mediating cocaine reward (Koob and Bloom 1988) and motivated behaviors (Wise and Bozarth 1987). Elevations in VTA 5-HT levels have been shown to increase both the local release of DA (Beart and McDonald 1982) and dopaminergic activity in the NAcc (Guan and McBride 1989). Moreover, DA release from nigrostriatal, mesoaccumbal and mesocortical DA terminals is potentiated by the local application 5-HT or specific 5-HT agonists (Benloucif and Galloway 1991; Chen et al. 1991, 1992; Nissbrandt et al. 1992; Benloucif et al. 1993; Galloway et al. 1993; Parsons and Justice 1993; Chen and Reith 1994; Yadid et al. 1994; however, see Chen and Reith 1995). While the specific 5-HT receptor(s) involved in this interactive process have not yet been clearly identified, the 5-HT_{1B} and 5-HT_{1D} receptor subtypes have been the most commonly implicated (see above references).

While the literature suggests an involvement of 5-HT in the modulation of the reinforcing effects of cocaine, ligands specific for individual 5-HT receptor subtypes have proven ineffective at altering behaviors maintained by cocaine administration. 5-HT receptor antagonists do not alter either cocaine self-administration (Peltier and Schenk 1991; Lacosta and Roberts 1993) or the stimulus properties of cocaine (Colpaert et al. 1976; McKenna and Ho 1980; Paris and Cunningham 1991; Baker et al. 1993; Peltier et al. 1994). Moreover, neither direct (Colpaert et al. 1979; McKenna and Ho 1980; Winters and Slifer 1989) nor indirect 5-HT receptor agonists (McKenna and Ho 1980; Cunningham and Callahan 1991; Baker et al. 1993) generalize to cocaine in discrimination tests.

One possible explanation for the negative findings with specific 5-HT receptor ligands relates to the fact that as indirect agonists, cocaine and other psychostimulants induce a non-specific stimulation of all 15 of the 5-HT receptor subtypes identified so far (Hoyer et al. 1994). Because these individual receptors have differing and sometimes opposing effects on neuronal transmission (for review see Hoyer et al. 1994), the

effect(s) of individual 5-HT receptor stimulation or blockade on psychostimulant reinforcement may be masked in studies using an indirect agonist as a reinforcer. Thus, the purpose of the present experiment was to examine the effect of 5-HT_{1B} receptor stimulation on GBR-12909 self-administration. GBR-12909 is a potent inhibitor of DA uptake which displays little affinity for the 5-HT and NE reuptake transporters (Heikkila and Manzino 1984; Anderson 1989). Thus, GBR-12909 self-administration provides a model of reinforcement mediated primarily via DA neurotransmission. The effect of 5-HT_{1B} receptor stimulation (by the agonist CGS-12066B) was examined in view of neurochemical evidence indicating a stimulatory role for this receptor on DA neurotransmission (Benloucif and Galloway 1991; Nissbrandt et al. 1992; Benloucif et al. 1993; Galloway et al. 1994). For comparison, the effect of 5-HT_{1B} receptor stimulation on cocaine self-administration was also examined.

Materials and methods

Subjects

Twenty-five male albino Wistar rats (Charles River, Kingston, Calif. USA weighing 220–260 g upon arrival) were habituated to the animal colony for 1 week with food and water available ad libitum, and were handled daily. All animals were group housed (two or three/cage) and maintained on a reverse 12-h light/dark cycle (lights on at 10 p.m.) in a humidity and temperature controlled (22°C) vivarium. All behavioral procedures began between 1 and 3 h after the onset of the dark phase (approximately 12:30 p.m.) and were conducted using a within-subject design. Data are presented from all animals that completed an experimental design. All procedures were conducted in strict adherence to the *National Institutes of Health Guide for the Care and Use of Laboratory Animals*.

Surgery

Rats were anesthetized with a halothane/oxygen vapor mixture (1.0–1.5%) and implanted with chronic intravenous catheters as previously described (Emmett-Oglesby and Lane 1992) with minor modifications (Caine et al. 1993). Briefly, the catheters consisted of a 12 cm length of silastic tubing fitted to a guide cannula (Plastics One, Roanoke Va., USA) bent at a right angle and encased in dental cement anchored with a 3 cm square of durable mesh. The catheter tubing was passed subcutaneously from the animal's back to the right jugular vein which was punctured with a 26-gauge needle. Silastic tubing (37 mm) was inserted into the vein, and tied gently with suture thread. All animals were allowed to recover for a minimum of 7 days before being given access to drug self-administration. Catheters were flushed daily with sterile physiological saline containing heparin (30 USP units/ml) and streptokinase (0.67 mg/ml).

Catheter patency

The integrity of a catheter was tested whenever an animal not receiving drug pretreatments displayed behavior outside baseline parameters. If intravenous blood could not be readily withdrawn via

the catheter, 0.1 ml of the ultra-short-acting barbiturate anesthetic Brevital Sodium (1% methohexital sodium, Eli Lilly, Indianapolis, Ind., USA) was administered through the catheter and the animal was observed. Animals with patent catheters exhibited prominent signs of anesthesia (pronounced loss of muscle tone) within 3 s of IV injection. Animals with faulty catheters were recatheterized on the opposite jugular vein. Data collected from animals that did not complete all the tests in an experimental design were excluded.

Apparatus

Self-administration chambers consisted of operant boxes equipped with a single retractable lever which was extended approximately 1 inch into the chamber at the start of the session. A light above the lever signaled delivery of a drug injection. A food hopper was located to the left of the lever. Drug infusions were delivered by a syringe pump equipped with a 5 rpm motor (Razel Scientific Instruments, Model A, Stamford, Conn., USA) activated for 4 s to deliver drug in a volume of 0.1 ml through a polyethylene tube attached to the catheter on the animals' back via a stainless steel liquid swivel.

Self-administration training

Prior to surgery, rats were food restricted (20 g chow/rat per day) and operantly trained to press a lever for 0.45-mg food pellets (Bio-Serve, Frenchtown, N.J., USA). Once stable responding on a fixed ratio 5 (FR 5) schedule of reinforcement was achieved the animals were given ad libitum access to food for the remainder of the experiment. The animals then received chronic jugular catheter implants. Following surgery, animals were divided into two groups, each of which was then trained to self-administer either GBR-12909 or cocaine, respectively, on an FR5 schedule of reinforcement. Thus, GBR-12909 self-administering animals in this experiment were not exposed to cocaine at any time. The animals were allowed a post-operative recovery period of 7 days, after which they were allowed to acquire drug self-administration by autoshaping, 3 h per day, 6 days a week. The training doses of each drug were 83 µg/injection GBR-12909 and 0.25 mg/injection cocaine. The daily 3-h self-administration sessions were continued until the total number of drug infusions per session stabilized to within ± 10% for 3 consecutive days (baseline criterion). With the exception of the first self-administration session, all sessions commenced with two non-contingent infusions of the drug dose for that session. The lever was then extended after which time the completion of each FR 5 resulted in an injection signaled immediately by a cue light, which remained lit for a 20-s timeout period, during which responses were recorded but not reinforced.

Experimental design

After baseline criteria were met in each group for the training doses of GBR-12909 and cocaine, the dose-effect functions for each drug and the effect of CGS-12066B pretreatment on these dose-effect functions were established. The criterion for the start of unit dose or drug interaction tests was three consecutive self-administration sessions with less than ± 10% variation in the total number of injections earned. Dose-effect functions (GBR-12909; 0, 10.4, 20.75, 41.5, 83, 166 µg per injection; Cocaine; 0, 0.03, 0.06, 0.125, 0.25, 0.5 mg per injection) were generated using a within-subject counter-balanced design ($n = 7-12$ for all experiments). On one of the final baseline criterion days for each dose of self-administered drug, a control injection of saline (0.6 ml/kg, IP) was administered 15 min prior to the self-administration session. Because CGS-12066B also

has affinity for the 5-HT_{1A} receptor (Hoyer et al. 1994) the effect of 8-OH-DPAT pretreatment on the self-administration of 83 µg/injection GBR-12909 was also investigated. CGS-12066B (IP) and 8-OH-DPAT (SC) pretreatments were administered 15 min prior to testing in a volume of 0.6 ml/kg.

Drugs

GBR-12909 HBr was generously provided by Novo Nordisk A/S (The Netherlands) and was dissolved in 0.9% saline by sonication and gentle heating. Cocaine HCl was obtained from Sigma (St Louis, Mo., USA) and was dissolved in 0.9% saline. CGS-12066B maleate was obtained from Research Biochemicals International (RBI, Natick, Mass., USA) and was dissolved in 20 µl 0.1 N HCl, then diluted 100-fold with 0.9% saline. All GBR-12909 and CGS-12066B solutions were made fresh daily. All doses refer to the weights of the respective salts.

Statistics


All results were analyzed using a repeated measures analysis of variance (ANOVA) with the drug pretreatment (either CGS-12066B or 8-OH-DPAT) as the within-subject factor. For experiments involving a single dose of self-administered GBR-12909 or cocaine, the effects of the serotonin agonist pretreatment were analyzed by one-way ANOVA followed by Fisher's PLS test to compare various doses of agonist pretreatment with vehicle treatment. For experiments examining the effects of CGS-12066B pretreatment on the drug self-administration dose-effect function, drug dose (GBR-12909 or cocaine) and CGS-12066B pretreatment dose were analyzed by a two-way ANOVA with repeated measures. To identify significant effects of CGS-12066B at different doses of either GBR-12909 or cocaine, simple effects ANOVA was used. A shift of the dose-effect function was defined by a significant drug (GBR-12909 or cocaine) dose × CGS-12066B interaction, in the presence of significant simple effects of CGS-12066B to increase self-administration on the ascending limb of the dose-effect function, as well as to decrease self-administration on the descending limb. Differences were considered significant at $P < 0.05$.

Results

Effect of CGS-12066B on GBR-12909 self-administration

The training dose of GBR-12909 (83 µg/injection) maintained stable, titrated (i.e. stable and regular inter-injection intervals) self-administration behavior with a mean drug intake of 43.7 ± 5.5 (mean ± SEM) injections per 3-h session. The average weight of the animals was 0.51 ± 0.01 kg; thus the training dose of GBR-12909 corresponded to 163 µg/kg per injection. Pretreatment with the 5-HT_{1B} agonist CGS-12066B (1–10 mg/kg, IP; $n = 9$) dose-dependently reduced GBR-12909 self-administration by increasing the time interval between reinforcers [$F(3,24) = 5.339$, $P < 0.01$], without disrupting stable drug intake (Fig. 1). Both 3 mg/kg and 10 mg/kg CGS-12066B produced significant decreases in GBR-12909 self-administration ($P < 0.05$).

Fig. 1 Effect of pretreatment with the 5-HT_{1B} agonist CGS-12066B (1–10 mg/kg, IP) on the self-administration of the training dose (83 µg/injection) of GBR-12909 ($n = 9$). *Top panel:* CGS-12066B pretreatment dose-dependently reduced the amount of self-administered GBR-12909 in a 3-h session. *Asterisks* denote significant differences from vehicle control, by pairwise comparison following overall main effects by ANOVA. *Bottom panel:* event record of reinforcer delivery for one rat self-administering GBR-12909 after pretreatment with vehicle or CGS-12066B (1–10 mg/kg, IP). Each *horizontal line* represents a separate 3-h self-administration session, with time progressing from the left to the right. Each *vertical tick mark* denotes delivery of a single reinforcer following completion of an FR5



GBR-12909 self-administration produced an inverted U-shaped dose-effect function [$F(4,44) = 15.402$, $P < 0.0001$] characteristic of psychostimulant self-administration. Pretreatment with CGS-12066B (3 mg/kg, IP; $n = 12$) produced a significant GBR-12909 dose \times CGS-12066B interaction [$F(4,44) = 2.9$, $P < 0.05$]. Simple main effects tests indicated that CGS-12066B pretreatment shifted the GBR-12909 dose-effect function to the left (Fig. 2); the minimum effective dose of GBR-12909 to maintain self-administration was lowered [$F(1,11) = 4.9$ and 11.2 ; $P < 0.05$ and $P < 0.01$ for the 10 and 21 µg/injection doses of GBR-12909, respectively], while at the same time the self-administration of higher doses was decreased [$F(1,11) = 14.5$, 11.2 and 0.9 ; $P < 0.05$, $P < 0.006$ and NS for the 42, 83 and 166 µg/injection doses of GBR-12909, respectively]. There was no significant effect of saline pretreatment on GBR-12909 self-administration. Self-administration was not reliably maintained when saline was substituted for GBR-12909 (Fig. 2), and there was no significant effect of CGS-12066B on responding for saline [$F(1,11) = 0.258$, NS].

Effect of 8-OH-DPAT on GBR-12909 self-administration

In a separate group of animals ($n = 7$), the effect of pretreatment with the selective 5-HT_{1A} receptor agonist 8-OH-DPAT (0.03, 0.1 and 1.0 mg/kg, SC) on the self-administration of GBR-12909 (83 µg/injection)

Table 1 Effect of 8-OH-DPAT pretreatment on the self-administration of GBR-12909 (83 µg/injection; $n = 7$). The number of GBR-12909 self-injections for each hour of the 3-h sessions is shown. There was no effect of 8-OH-DPAT pretreatment at any dose (0.03, 0.1 and 1.0 mg/kg, SC) on the self-administration of GBR-12909

| 8-OH-DPAT pretreatment dose (mg/kg, IP) | Number of GBR-12909 Injections (mean \pm SEM) | | |
|---|---|--------------|--------------|
| | Hour 1 | Hour 2 | Hour 3 |
| Saline | 21 \pm 1.7 | 12 \pm 2.0 | 12 \pm 1.3 |
| 0.03 | 19 \pm 2.2 | 14 \pm 1.0 | 13 \pm 1.7 |
| 0.1 | 18 \pm 2.2 | 11 \pm 2.7 | 14 \pm 2.6 |
| 1.0 | 19 \pm 1.1 | 11 \pm 2.4 | 12 \pm 2.1 |

Table 2 Effect of CGS-12066B pretreatment on the self-administration of cocaine with cocaine doses on the ascending (0.06 mg/injection) and descending (0.25 mg/injection) limb of the dose-effect function ($n = 7$). The number of cocaine self-injections for each hour of the 3-h sessions is shown. There was no effect of CGS-12066B pretreatment at any dose (1.0, 3.0, 10 mg/kg, IP) on cocaine self-administration at either of the cocaine doses examined

| CGS-12066B pretreatment dose (mg/kg, IP) | Cocaine dose (mg/inj, IV) | Number of cocaine injections (mean \pm SEM) | | |
|--|---------------------------|---|---------------|----------------|
| | | Hour 1 | Hour 2 | Hour 3 |
| Saline | 0.25 | 20 \pm 1.1 | 14 \pm 1.1 | 13.8 \pm 1.3 |
| 1.0 | 0.25 | 19 \pm 1.4 | 13 \pm 0.9 | 12 \pm 0.8 |
| 3.0 | 0.25 | 20 \pm 1.3 | 14 \pm 0.9 | 13 \pm 0.7 |
| 10.0 | 0.25 | 19 \pm 1.2 | 14 \pm 0.9 | 13 \pm 0.9 |
| Saline | 0.06 | 36 \pm 10.5 | 29 \pm 11.8 | 21 \pm 10.8 |
| 1.0 | 0.06 | 38 \pm 9.8 | 27 \pm 12.0 | 22 \pm 11.5 |
| 3.0 | 0.06 | 34 \pm 10.5 | 30 \pm 11.2 | 25 \pm 11.8 |
| 10.0 | 0.06 | 37 \pm 11.2 | 27 \pm 10.5 | 23 \pm 11.5 |




Fig. 2 Effect of pretreatment with CGS-12066B (3 mg/kg, IP) on the GBR-12909 self-administration dose-effect function ($n = 12$). Symbols adjacent to the vertical axis represent the effect of saline (○) or CGS-12066B (●) pretreatment on saline self-administration (GBR dose = 0). Asterisks denote significant simple main effects of CGS-12066B following significant CGS-12066B \times GBR-12909 main interaction by two-way ANOVA

was investigated. There was no effect of 8-OH-DPAT on GBR-12909 self-administration at any of the pretreatment doses tested [$F(3,18) = 0.514$; NS; see Table 1].

Effect of CGS-12066B on cocaine self-administration

Cocaine at the training dose of 0.25 mg/injection also maintained stable, titrated self-administration with a mean drug intake of 48.7 ± 6.1 injections per 3-h session. Pretreatment with the 5-HT_{1B} agonist CGS-12066B (1–10 mg/kg, IP; $n = 7$) had no significant effect on the self-administration of this dose of cocaine [$F(3,18) = 2.06$, NS; see Table 2]. These same doses of the 5-HT_{1B} agonist also failed to modify the self-




Fig. 3 Effect of pretreatment with CGS-12066B (3 mg/kg, IP) on the cocaine self-administration dose-effect function ($n = 7$). Symbols adjacent to the vertical axis represent the effect of saline (□) or CGS-12066B (■) pretreatment on saline self-administration (cocaine dose = 0)

administration of a lower dose of cocaine (0.06 mg/injection) [$F(3,18) = 1.98$, NS; see Table 2].

Cocaine self-administration produced a characteristic inverted U-shaped dose-effect function [$F(4,24) = 7.1$, $P < 0.001$] ($n = 7$). Pretreatment with CGS-12066B (3 mg/kg, IP) had no significant effect on the cocaine dose-effect function as demonstrated by a lack of a significant cocaine dose \times CGS-12066B main interaction [$F(4,24) = 0.253$, NS; Fig. 3]. There was also no significant effect of saline pretreatment on cocaine self-administration. Self-administration was not reliably maintained when saline was substituted for cocaine (Fig. 3), and there was no significant effect of CGS-12066B on responding for saline [$F(1,6) = 0.477$, NS].

Discussion

5-HT_{1B} receptor stimulation was found to enhance DA-mediated reinforcement as demonstrated by a significant leftward shift of the GBR-12909 self-administration dose-effect function (Fig. 2). Pretreatment with the 5-HT_{1A/1B} receptor agonist CGS-12066B not only decreased the self-administration of GBR-12909 on the descending limb of the dose-effect function (by increasing the inter-injection interval), but also lowered the minimum dose of GBR-12909 which maintains self-administration on a fixed-ratio schedule (Fig. 2). Moreover, this 5-HT_{1B} receptor-induced potentiation of GBR-12909 reinforcement was dose-dependent, as indicated by the progressive decrease in the self-administration of GBR-12909 with increasing doses of CGS-12066B (Fig. 1). The 5-HT_{1A} receptor-selective agonist 8-OH-DPAT did not alter GBR-12909 self-administration, suggesting that 5-HT_{1A} receptors are not involved in the potentiating actions of CGS-12066B. Finally, there was no effect of CGS-12066B

pretreatment on cocaine self-administration (Fig. 3), suggesting that the stimulation of other 5-HT receptor subtypes by the indirect agonist effects of cocaine may mask the potentiating effects of 5-HT_{1B} receptor stimulation.

GBR-12909 maintained stable, dose-dependent self-administration, in agreement with previous reports of its self-administration by rats (Roberts 1993) and monkeys (Kleven et al. 1988; Bergman et al. 1989; Howell and Byrd 1991). Reinforcing actions of GBR-12909 would be expected based on reports indicating that this uptake inhibitor substitutes for the discriminative properties of cocaine in rats (Cunningham and Callahan 1991; Witkin et al. 1991) and monkeys (Melia and Spealman 1991) and cross-sensitizes to the locomotor-stimulant effects of cocaine (Baldo and Kelley 1991). Similar to cocaine (Markou and Koob 1991), GBR-12909 also lowers the threshold for electrical brain stimulation reward (Rompré and Bauco 1990). These findings suggest that GBR-12909 and cocaine share many of the same properties, and likely activate the same neurochemical pathway, namely the mesocorticolimbic DA system.

In the present study, rats that had no prior psychostimulant exposure readily acquired GBR-12909 self-administration (83 µg/injection; FR5) with an acquisition timecourse similar to cocaine self-administration (0.25 mg/injection; FR5). While the dose range of self-administered GBR-12909 was much lower in the present study than that previously investigated in rats (Roberts 1993), a similar dose of GBR-12909 in each of these studies produced comparable amounts of drug intake (8.36 injections/h with a dose of 325 µg/kg per injection presently versus approximately eight injections/h with a dose of 375 µg/kg per injection (Roberts 1993). Additionally, the present finding that similar amounts of drug intake are maintained both by cocaine and a 3-fold lower dose of GBR-12909 (0.25 mg/injection versus 83 µg/injection respectively) is in agreement with previous findings using an FR schedule of reinforcement in rats (Roberts 1993).

Stimulation of 5-HT_{1B} receptors by the 5-HT₁ receptor agonist CGS-12066B produced a leftward shift of the GBR-12909 dose effect function (Fig. 2), suggesting that stimulation of these receptors facilitates DA-mediated reinforcement. This finding is supported by recent studies indicating that 5-HT_{1B} receptor stimulation enhances DA efflux in the striatum and limbic forebrain (Benloucif and Galloway 1991; Nissbrandt et al. 1992; Benloucif et al. 1993; Galloway et al. 1993), increases locomotor activity (Green et al. 1984; Oberlander et al. 1986; Tricklebank et al. 1986; Cheetham and Heal 1993), produces a cocaine-like stimulus in rats (Callahan and Cunningham 1995), and shifts the cocaine discrimination dose-effect function to the left (Callahan and Cunningham 1995).

CGS-12066B has been reported to display selectivity for 5-HT_{1B} receptors (Schoeffter and Hoyer 1989;

Middlemiss and Hutson 1990), but it also has appreciable affinity for 5-HT_{1A} receptors (Neale et al. 1987; Schoeffter and Hoyer 1989; Macor et al. 1990). Thus the effect of 5-HT_{1A} receptor stimulation on GBR-12909 self-administration was also investigated. Over a wide dose range, pretreatment with the selective 5-HT_{1A} receptor agonist 8-OH-DPAT (Glennon and Dukat 1991; Hoyer et al. 1994) had no significant effect on GBR-12909 self-administration. The doses of 8-OH-DPAT examined encompass the low-dose inhibition of dorsal and median raphe neuronal firing which results in decreased 5-HT efflux in the VTA (0.03 mg/kg, IP; Blier and DeMontigny 1987; Lum and Piercey 1988; Chen and Reith 1995) and higher dose induction of the "serotonin syndrome" (1.0 mg/kg, IP; Arvidsson et al. 1981; Dourish et al. 1985). The lack of effect of 8-OH-DPAT suggests that 5-HT_{1A} receptors are not involved in the stimulatory effects of CGS-12066B on GBR-12909 reinforcement. While CGS-12066B also has an affinity for 5-HT_{2C} receptors (Schoeffter and Hoyer 1989), Callahan and Cunningham (1995) have recently provided evidence that this receptor subtype induces opposite effects on the discriminative properties of cocaine as does the 5-HT_{1B} receptor subtype (i.e. inhibition versus potentiation), suggesting that 5-HT_{2C} stimulation might inhibit psychostimulant reinforcement. In support of this finding, the 5-HT_{2C} receptor agonist mCPP (Schoeffter and Hoyer 1989) dose-dependently *increases* the self-administration of GBR-12909 (83 µg/injection; Parsons et al., unpublished findings). Coupled with the observation that CGS-12066B has minimal affinity for both D₁ and D₂ dopamine receptors and α_1 -, α_2 -, or β -adrenergic receptors (Neale et al. 1987), these findings suggest that the potentiation of GBR-12909 reinforcement by CGS-12066B observed here is likely to result from the stimulation of 5-HT_{1B} receptors.

One possible mechanism for the facilitatory action of CGS-12066B on GBR-12909 self-administration is a 5-HT_{1B} receptor-induced increase in DA efflux. This effect could occur via a reduction in the inhibitory input to mesoaccumbens DA neurons, since 5-HT_{1B} (rat) or 5-HT_{1D} (guinea pig) receptor stimulation has recently been shown to inhibit the release of GABA onto A10 DA neurons (Johnson et al. 1992; Cameron and Williams 1994). These findings are in agreement with the distribution of 5-HT_{1B} receptors which are abundant in the substantia nigra and the VTA in rats, where they appear to be localized on the terminals of GABAergic afferents emanating from the caudate-putamen and NAcc (Boschert et al. 1993). This proposed mechanism may correlate with the observations that local administration of 5-HT into the VTA increases mesoaccumbens DA release via interactions with 5-HT_{1B} receptors (Guan and McBride 1988) and that mesocortical DA efflux is potentiated by the peripheral pretreatment with 5-HT_{1B} agonists (Nissbrandt et al. 1992). In addition, DA efflux is increased by local

administration of 5-HT_{1B} receptor agonists (Benloucif and Galloway 1991; Benloucif et al. 1993; Galloway et al. 1993), although the mechanism for this effect has not been fully characterized. Thus, stimulation of 5-HT_{1B} receptors by CGS-12066B may enhance DA neurotransmission both in the cell body and terminal regions, which may produce the presently observed leftward shift of the GBR-12909 self-administration dose-effect function.

An alternate mechanism by which 5-HT_{1B} receptor stimulation potentiates GBR-12909 reinforcement may be via a reduction in 5-HT efflux. There is ample evidence that 5-HT_{1B} receptors function as terminal (Middlemiss 1985, 1986; Engel et al. 1986; Limberger et al. 1991) and somatodendritic (Davidson and Stamford 1995; Pineyro et al. 1995) autoreceptors, and several reports suggest an inverse relationship between extracellular 5-HT levels and the reinforcing effects of psychostimulants. For example, depletion of extracellular 5-HT in the forebrain by 5,7-dihydroxytryptamine enhances the reward magnitude of cocaine (Loh and Roberts 1990), while increased synaptic availability of 5-HT inhibits cocaine self-administration (Carroll et al. 1990a, b) and decreases the breaking point of a progressive ratio schedule in cocaine self-administering rats (Richardson and Roberts 1991). Thus, in the present study, pretreatment with CGS-12066B may result in decreased basal 5-HT efflux which results in the enhancement of the reinforcing properties of GBR-12909. However, since 8-OH-DPAT also decreases 5-HT efflux (Chen and Reith 1995), this argument is weakened by the lack of effect of this 5-HT_{1A} receptor agonist on GBR-12909 self-administration. Moreover, clinical reports indicate that tryptophan depletion attenuates the acute euphoria induced by cocaine in humans (Aronson et al. 1995). It is possible, however, that the differential locations of 5-HT_{1A} (somatodendritic, post-synaptic in terminal fields; Hall et al. 1985; Verge et al. 1986) and 5-HT_{1B} (primarily pre-synaptic in terminal fields; Engel et al. 1986; Hamon et al. 1990; Limberger et al. 1991) receptors may be significant with regard to the differential effects of these receptors on GBR-12909 reinforcement.

Unlike GBR-12909 self-administration, cocaine self-administration was unaltered by 5-HT_{1B} receptor stimulation (Fig. 3). The median dose of CGS-12066B (3 mg/kg) was tested on the entire cocaine dose-effect function, as were various doses of CGS-12066B (1–10 mg/kg) both on the ascending and descending limbs of the cocaine dose-effect function. In all situations examined, CGS-12066B was ineffective at modulating cocaine self-administration on a fixed ratio schedule of reinforcement. It should be noted, however, that modulations of some phenomena such as motivation are more apparent on schedules of reinforcement other than the fixed ratio (Loh and Roberts 1990). It may be possible that positive effects of CGS-12066B on cocaine self-administration would be

observed on a different schedule of reinforcement such as a progressive ratio.

Nonetheless, the present finding that CGS-12066B enhances the reinforcing effects of GBR-12909 self-administration but does not alter cocaine self-administration suggests that the effects of 5-HT_{1B} receptor stimulation on DA-mediated reinforcement are somehow less apparent in the presence of the indirect 5-HT and/or NE agonist properties of cocaine. One explanation for this effect is that the simultaneous stimulation of multiple 5-HT receptor subtypes in the presence of cocaine masks or counters the effect of 5-HT_{1B} receptor stimulation. While the influence of other 5-HT receptor subtypes on reinforcement is not clear, recent findings by Callahan and Cunningham (1995) indicate that while 5-HT_{1B} receptor stimulation facilitates the stimulus effects of cocaine, 5-HT_{2C} receptor stimulation is inhibitory on this process. If the stimulus properties of a drug predict the drug's reinforcing properties, it may be that the concurrent stimulation of the 5-HT_{2C} receptor during cocaine self-administration reverses or blocks the effects of 5-HT_{1B} receptor stimulation. It should be noted, however, that while the 5-HT_{1B} agonist RU 24969 produced a leftward shift of the cocaine dose-effect curve in drug discrimination tests, CGS-12066B was ineffective (Callahan and Cunningham 1995). The differential effects of these agonists on cocaine discrimination may reflect their affinities for the 5-HT_{1B} and 5-HT_{2C} receptors, since the selectivity of RU 24969 for the 5-HT_{1B} receptor versus the 5-HT_{2C} receptor is greater than the selectivity of CGS-12066B for these receptors (Schoeffter and Hoyer 1989). The selectivities of these compounds for the 5-HT_{1B} receptor versus the 5-HT_{1A} receptor may also be important in light of reports that suggest a synergistic action of these receptors (Berendsen and Broekkamp 1990; Layer et al. 1992). CGS-12066B has also been found to have weak agonist efficacy in behavioral tests (Cheetham and Heal 1993) and thus it may be that the differential effects of CGS-12066B and RU 24969 on cocaine discrimination reflects a difference in potency at the 5-HT_{1B} receptor, rather than different selectivities for various 5-HT receptor subtypes. It is possible that a more potent and selective 5-HT_{1B} agonist than CGS-12066B, such as RU 24969, would have greater effects on GBR-12909 self-administration and would also potentiate the reinforcing properties of cocaine, a hypothesis supported by preliminary studies in rats (Parsons et al., unpublished observations).

An alternate explanation for the lack of effect of CGS-12066B on cocaine self-administration is that 5-HT_{1B} receptors are already maximally stimulated during cocaine self-administration (via cocaine-induced increases in synaptic 5-HT levels), making the addition of a 5-HT_{1B} agonist inconsequential. However, under these circumstances it would be expected that CGS-12066B would positively effect sub-threshold doses of cocaine without any effect at doses higher on the dose-

effect function, an effect which was not observed in the present study. Additionally as noted above, preliminary studies indicate that the more potent 5-HT_{1B} agonist RU 24969 produces a leftward shift of the cocaine self-administration dose-effect function (Parsons et al. unpublished observations). Together these findings suggest that 5-HT_{1B} receptors are not maximally stimulated during cocaine self-administration.

While the involvement of 5-HT_{1B} receptors in the acute reinforcing effects of cocaine is not clear at the present time, it is possible that the role of this receptor in mediating the behavioral effects of cocaine may be more pronounced following chronic cocaine exposure. Extended cocaine self-administration results in robust decrements in ambient extracellular 5-HT levels (Parsons et al. 1995) and a substantial literature indicates an inverse relationship between 5-HT levels and 5-HT_{1B} binding density and/or sensitivity (Weissmann et al. 1986; Offord et al. 1988; Van de Kar et al. 1989; Crino et al. 1990; Frankfurt et al. 1993; Manrique et al. 1993, 1994; Pranzatelli and Razi 1994). Thus it may be that 5-HT_{1B} receptor function is enhanced following chronic cocaine exposure, a proposal which is supported by recent endocrinological studies (Levy et al. 1992). An involvement of 5-HT_{1B} receptors in the motor sensitizing effects of repeated cocaine exposure may also be inferred from the finding that 5-HT_{1B} "knock-out" mice do not develop the increase in cocaine-induced stereotyped behaviors that wild type control animals do after chronic cocaine administration (Searce et al. 1995).

In addition to reports of alterations in 5-HT_{1B} receptor function specifically, there is substantial evidence that repeated cocaine exposure results in a general alteration of 5-HT function. Extended exposure to cocaine has been shown to result in significant decrements in 5-HT neuronal activity (Cunningham 1995) and alterations in 5-HT receptor sensitivity (Cunningham et al. 1992; Baumann et al. 1993; King et al. 1993; Levy et al. 1994; Baumann and Rothman 1995). Conversely, repeated cocaine exposure enhances the cocaine-induced elevations of both 5-HT (Parsons and Justice 1993) and DA (Kalivas and Duffy 1990; Pettit et al. 1990; Parsons and Justice 1993) in several brain regions and results in an enhanced ability of exogenous 5-HT to elevate NAcc DA levels (Parsons et al. 1995; but see Galloway and Suchowski 1995). Together, these findings indicate that chronic cocaine exposure results in altered serotonergic function, both within the 5-HT neurotransmitter system itself and potentially also *between* the serotonergic system and the dopaminergic system. A possible functional significance of these alterations may be inferred from the finding that repeated cocaine exposure produces cross-tolerance to the cocaine analogue WIN 35,428, but does not produce cross-tolerance to GBR-12909 (Katz et al. 1993). Because WIN 35,428 has affinity for the 5-HT uptake transporter (Rudnick and Wall 1991) and produces

similar effects on serotonergic activity as cocaine (Cunningham and Lakoski 1990) while GBR-12909 does not (Heikkila and Manzino 1984; Anderson et al. 1989), these findings may suggest a serotonergic component in the processes of cocaine tolerance. However, a contribution of NE neurotransmission to the cross-tolerance between cocaine and WIN 35,428 cannot be ruled out.

In summary, 5-HT_{1B} receptor stimulation was found to enhance the reinforcing effects of the selective DA uptake inhibitor GBR-12909. However, there was no effect of 5-HT_{1B} receptor stimulation on the self-administration of cocaine, suggesting that the simultaneous stimulation of other 5-HT receptor subtypes by the indirect agonist properties of cocaine masks the stimulatory effects of 5-HT_{1B} receptor stimulation. The 5-HT_{1B} receptor is the rat homologue of the 5-HT_{1D} receptor in humans (Hartig et al. 1992 for review), and these species specific receptor homologues are differentiated by a single amino acid (Oksenberg et al. 1992; Parker et al. 1993). Given the remarkable similarities between these receptors, the present finding of a stimulatory role of the 5-HT_{1B} receptor on DA-mediated reinforcement in rats may have direct relevance to the mechanisms of stimulant reinforcement and motivation in humans.

Acknowledgements Support for this work was provided by grants DA-05564 (L.H.P.), DA-08467 (G.F.K. and F.W.) and DA-07348 (F.W.) from the National Institute on Drug Abuse. This is publication number 9846-NP from The Scripps Research Institute.

References

- Anderson PH (1989) The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. *Eur J Pharmacol* 166:493–504
- Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, Heninger GR, Price LH (1995) Serotonergic mechanisms of cocaine effects in humans. *Psychopharmacology* 119:179–185
- Arvidsson L-E, Hacksell U, Nilsson JLG, Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom H (1981) 8-Hydroxy-2-(di-*n*-propylamino) tetralin, a new centrally acting 5-HT receptor agonist. *J Med Chem* 24:921–923
- Azmitia EC, Segal M (1978) An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei of the rat. *J Comp Neurol* 179:641–668
- Baker LE, Riddle EE, Saunders RB, Appel JB (1993) The role of monoamine uptake in the discriminative stimulus effects of cocaine and related compounds. *Behav Pharmacol* 4:69–79
- Baldo BA, Kelley AE (1991) Cross-sensitization between cocaine and GBR 12909, a dopamine uptake inhibitor. *Brain Res Bull* 27:105–108
- Baumann MH, Rothman RB (1995) Repeated cocaine administration reduces 5-HT_{1a}-mediated prolactin secretion in rats. *Neurosci Lett* 193:9–12
- Baumann MH, Brockington AM, Rothman RB (1993) Withdrawal from chronic cocaine enhances behavioral sensitivity to the 5-HT_{2/1c} agonist DOI. *Biol Psychiatry* 34:576–572
- Beart PM, McDonald D (1982) 5-Hydroxytryptamine and 5-hydroxytryptaminergic-dopaminergic interactions in the ventral tegmental area of rat brain. *J Pharm Pharmacol* 34:591–593

- Benloucif S, Galloway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. *Eur J Pharmacol* 200:1–8
- Benloucif S, Keegan MJ, Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. *J Pharmacol Exp Ther* 265:373–377
- Berendsen HHG, Broekkamp, CLE (1990) Behavioral evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. *Br J Pharmacol* 101:667–673
- Bergman J, Madras BK, Johnson SE, Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. *J Pharmacol Exp Ther* 251:150–155
- Bhat RV, Baraban JM (1993) Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. *J Pharmacol Exp Ther* 267:496–505
- Blier P, De Montigny C (1987) Modification of 5-HT neuron properties by sustained administration of the 5-HT_{1a} agonist gepirone: electrophysiological studies in the rat brain. *Synapse* 1:470–480
- Boschert U, AitAmara D, Segu L, Hen R (1993) The mouse 5-hydroxytryptamine 1B receptor is localized predominantly on axon terminals. *Neuroscience* 58:167–182
- Caine SB, Lintz R, Koob GF (1993) Intravenous drug self-administration techniques in animals. In: Sahgal A (ed) *Behavioral neuroscience: a practical approach*. Oxford University Press, Oxford, pp 117–143
- Callahan PM, Cunningham KA (1995) Modulation of the discriminative stimulus properties of cocaine by 5-HT_{1B} and 5-HT_{2C} receptors. *J Pharmacol Exp Ther* 274:1414–1424
- Cameron DL, Williams JT (1994) Cocaine inhibits GABA release in the VTA through endogenous 5-HT. *J Neurosci* 14:6763–6767
- Carroll ME, Lac ST, Ascencio M, Kragh R (1990a) Fluoxetine reduces intravenous cocaine self-administration in rats. *Pharmacol Biochem Behav* 35:237–244
- Carroll ME, Lac ST, Ascencio M, Kragh R (1990b) Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. *Psychopharmacology* 100:293–300
- Cheetham SC, Heal DJ (1993) Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT_{1b} receptor. *Br J Pharmacol* 110:1621–1629
- Chen J, van Praag HM, Gardner EL (1991) Activation of 5-HT₃ receptor by 1-phenylpiperazine increases dopamine release in the rat nucleus accumbens. *Brain Res* 543:354–357
- Chen J, Paredes W, van Praag HG, Lowinson JH, Garner EL (1992) Presynaptic dopamine release is enhanced by 5-HT₃ receptor activation in medial prefrontal cortex of freely moving rats. *Synapse* 10:264–266
- Chen NH, Reith MEA (1994) Autoregulation and monoamine interactions in the ventral tegmental area in the absence and presence of cocaine: a microdialysis study in freely moving rats. *J Pharmacol Exp Ther* 271:1597–1610
- Chen NH, Reith MEA (1995) Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-*n*-propylamino)tetralin. *J Neurochem* 64:1585–1597
- Colpaert FC, Niemegeers JE, Janssen AJ (1976) Cocaine cue in rats as it relates to subjective drug effects. *Eur J Pharmacol* 40:195–199
- Colpaert FC, Niemegeers JE, Janssen AJ (1979) Discriminative stimulus properties of cocaine: neuropharmacological characteristics as derived from stimulus generalization experiments. *Pharmacol Biochem Behav* 10:535–546
- Conrad L, Leohard C, Pfaff D (1974) Connections of the median and dorsal raphe nuclei in the rat: an autoradiographic and degeneration study. *J Comp Neurol* 156:179–206
- Crino PB, Vogt BA, Volicer L, Wiley RG (1990) Cellular localization of serotonin 1A, 1B and uptake sites in the cingulate cortex of the rat. *J Pharmacol Exp Ther* 252:651–656
- Cunningham KA (1995) Modulation of serotonin function by acute and chronic cocaine: neurophysiological analyses. In: Hammer RP Jr (ed) *The neurobiology of cocaine: cellular and molecular mechanisms*. CRC Press, Boca Raton New York London Tokyo, pp 121–144
- Cunningham KA, Callahan PM (1991) Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in rats. *Psychopharmacology* 104:177–180
- Cunningham KA, Lakoski JM (1990) The interaction of cocaine with serotonin dorsal raphe neurons. Single-unit extracellular recording studies. *Neuropsychopharmacology* 3:41–50
- Cunningham KA, Paris JM, Goeders NE (1992) Chronic cocaine enhances serotonin autoregulation and serotonin uptake binding. *Synapse* 11:112–123
- Davidson C, Stamford JA (1995) The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potentiated by both 5-HT-1A and 5-HT-1B/1D receptor antagonists. *Neurosci Lett* 188:41–44
- Dourish CT, Hutson PH, Curzon G (1985) Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-*n*-propylamino) tetralin (8-OH-DPAT). *Brain Res Bull* 15:377–384
- Emmett-Oglesby MW, Lane JD (1992) Tolerance to the reinforcing effects of cocaine. *Behav Pharmacol* 3:193–200
- Engel G, Gothert M, Hoyer D, Schlicker E, Hillenbrand K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT_{1B} binding sites. *Naunyn-Schmiedeberg's Arch Pharmacol* 332:1–7
- Frankfurt M, Medelson SD, McKittrick CR, McEwen BS (1993) Alterations of serotonin receptor binding in the rat hypothalamus following acute denervation. *Brain Res* 601:349–352
- Galloway MP, Suchowski CS (1995) Effects of repeated cocaine exposure on 5-HT facilitation on DA release: microdialysis studies in vivo. *Soc Neurosci Abstr* 21:716
- Galloway MP, Suchowski CS, Keegan MJ, Hjorth S (1993) Local infusion of the selective 5HT-1b agonist CP-93, 129 facilitates striatal dopamine release in vivo. *Synapse* 15:90–92
- Glennon RA, Dukat M (1991) Serotonin receptors and their ligands: a lack of selective agents. *Pharmacol Biochem Behav* 40:1009–1017
- Green AR, Guy AP, Gardner CR (1984) The behavioral effects of RU 24969, a suggested 5-HT-1B receptor agonist in rodents and the effect on the behavior of treatments with antidepressants. *Neuropharmacology* 23:655–661
- Guan X-M, McBride WJ (1989) Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. *Brain Res Bull* 23:541–547
- Hall MD, El Mestikawy S, Emerit MB, Pichat L, Hamon M, Gozlan H (1985) [³H]8-Hydroxy-2-(di-*n*-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. *J Neurochem* 44:1685–1696
- Hamon M, Collin E, Chantrel D, Daval G, Verge D, Bourgoin S, Cresselin F (1990) Serotonin receptors and the modulation of pain. In: Besson JM (ed) *Serotonin and pain*. Elsevier, Amsterdam, pp 53–72
- Hartig PR, Branchek TA, Weinshank RL (1992) A subfamily of 5-HT_{1d} receptor genes. *Trends Pharmacol Sci* 13:152–159
- Heikkila RE, Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. *Eur J Pharmacol* 103:241–248
- Hervé D, Pickel VM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. *Brain Res* 435:71–83
- Howell LL, Byrd LD (1991) Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. *J Pharmacol Exp Ther* 258:178–185

- Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacol Rev* 46:157–203
- Johnson SW, Mercuri NB, North RA (1992) 5-Hydroxytryptamine_{1B} receptors block the GABAB synaptic potential in rat dopamine neurons. *J Neurosci* 12:2000–2006
- Kalivas PW, Duffy P (1990) The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. *Synapse* 5:48–58
- Katz JL, Griffiths JW, Sharpe LG, De Souza EB, Witkin JM (1993) Cocaine tolerance and cross-tolerance. *J Pharmacol Exp Ther* 264:183–192
- King GR, Joyner CM, Ellinwood EH (1993) Withdrawal from continuous or intermittent cocaine: behavioral responsivity to 5-HT₁ receptor agonists. *Pharmacol Biochem Behav* 45:577–587
- Kleven MS, Anthony EW, Nielson EB, Woolverton WL (1988) Reinforcing and discriminative stimulus effects of GBR 12909 in rhesus monkeys. *Soc Neurosci Abstr* 14:305
- Koe BK (1976) Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. *J Pharmacol Exp Ther* 199:649–661
- Koob GF (1992) Dopamine, addiction and reward. *Semin Neurosci* 4:139–148
- Koob GF, Bloom FE (1988) Molecular and cellular mechanisms of drug dependence. *Science* 242:715–723
- Kuhar ML, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. *Trends Neurosci* 14:299–302
- Lacosta S, Roberts DCS (1993) MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. *Pharmacol Biochem Behav* 44:161–165
- Layer RT, Uretsky NJ, Wallace LJ (1992) Effect of serotonergic agonists in the nucleus accumbens on *d*-amphetamine-stimulated locomotion. *Life Sci* 50:813–820
- Levy AD, Baumann MH, Van de Kar LD (1994) Monoaminergic regulation of neuroendocrine function and its modification by cocaine. *Frontiers Neuroendocrinol* 15:85–156
- Levy AD, Rittenhouse PA, Li Q, Bonadonna AM, Alvarez Sanz MC, Kerr JE, Cothea CL, Van de Kar LD (1992) Repeated injections of cocaine inhibit the serotonergic regulation of prolactin and renin secretion in rats. *Brain Res* 580:6–11
- Limberger N, Deicher R, Starke K (1991) Species differences in presynaptic serotonin autoreceptors: mainly 5-HT_{1b} but possibly in addition 5-HT_{1d} in the rat, 5-HT_{1d} in the rabbit and guinea-pig brain cortex. *Naunyn-Schmiedeberg's Arch Pharmacol* 343:353–364
- Loh EA, Roberts DCS (1990) Break points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. *Psychopharmacology* 101:262–266
- Lum JT, Piercy MF (1988) Electrophysiological evidence that spiperone is an antagonist of 5-HT_{1a} receptors in the dorsal raphe nucleus. *Eur J Pharmacol* 149:9–15
- Macor JE, Burkhart CA, Heym JH, Ives JL, Lebel LA, Newman M, Nielsen JA, Ryan K, Schulz DW, Torgersen LK, Koe BK (1990) 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT_{1B}) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole. *J Med Chem* 33:2087–2093
- Manrique C, Segu L, Hery F, Hery M, Faudon M, Francois-Bellan AM (1993) Increase of central 5-HT_{1b} binding sites following 5,7-dihydroxytryptamine axotomy in the adult rat. *Brain Res* 623:345–348
- Manrique C, Francois-Bellan AM, Segu L, Becquet D, Hery M, Faudon M, Hery F (1994) Impairment of serotonergic transmission is followed by adaptive changes in 5-HT_{1b} binding sites in the rat suprachiasmatic nucleus. *Brain Res* 663:93–100
- Markou A, Koob GF (1991) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. *Physiol Behav* 51:111–119
- McGregor A, Lacosta S, Roberts DCS (1993) L-Tryptophan decreases the breaking point under a progressive ratio schedule of intravenous cocaine reinforcement in the rat. *Pharmacol Biochem Behav* 44:651–655
- McKenna ML, Ho BT (1980) The role of dopamine in the discriminative stimulus properties of cocaine. *Neuropharmacology* 19:297–303
- Melia KF, Speelman RD (1991) Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. *J Pharmacol Exp Ther* 258:626–632
- Middlemiss DN (1985) The putative 5-HT₁ receptor agonist, RU 24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-HT autoreceptor. *J Pharm Pharmacol* 37:434–438
- Middlemiss DN (1986) Blockade of the central 5-HT autoreceptor by β -adrenoceptor antagonists. *Eur J Pharmacol* 120:51–54
- Middlemiss DN, Hutson PH (1990) The 5-HT_{1b} receptors. *Ann NY Acad Sci* 600:132–148
- Neale RF, Fallon SL, Boyar WC, Wasley WF, Martin LL, Stone GA, Glaeser BS, Sinton CM, Williams M (1987) Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. *Eur J Pharmacol* 136:1–9
- Nissbrandt H, Waters N, Hjorth S (1992) The influence of serotonergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. *Naunyn-Schmiedeberg's Arch Pharmacol* 346:12–19
- Oberlander C, Blaquièrre B, Pujol JF (1986) Distinct functions for dopamine and serotonin in locomotor behavior: evidence using the s-HT₁ agonist RU 24969 in globus pallidus-lesioned rats. *Neurosci Lett* 67:113–118
- Offord SJ, Ordway GA, Frazer A (1988) Application of [¹²⁵I]-iodocyanopindolol to measure 5-hydroxytryptamine-1B receptors in the brain of the rat. *J Pharmacol Exp Ther* 244:144–150
- Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Mavlik S, Peroutka SJ, Ashkenazi A (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT_{1b} receptors. *Nature* 360:161–163
- Parent A, Descarries L, Beaudet A (1981) Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [³H]5-hydroxytryptamine. *Neuroscience* 6:115–138
- Paris JM, Cunningham KA (1991) Serotonin 5-HT₃ antagonists do not alter the discriminative stimulus properties of cocaine. *Psychopharmacology* 104:475–478
- Parker EM, Grisel DA, Iben LG, Shapiro RA (1993) A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine_{1B} receptors. *J Neurochem* 60:380–383
- Parsons LH, Justice JB, Jr (1993) Perfusate serotonin increases extracellular dopamine in the nucleus accumbens of the rat as measured by in vivo microdialysis. *Brain Res* 606:195–199
- Parsons LH, Koob GF, Weiss F (1995) Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. *J Pharmacol Exp Ther* 274:1182–1191
- Peltier R, Schenk S (1991) GR38032F, a serotonin 5-HT₃ antagonist, fails to alter cocaine self-administration in rats. *Pharmacol Biochem Behav* 39:133–136
- Peltier R, Schenk S (1993) Effects of serotonergic manipulations on cocaine self-administration in rats. *Psychopharmacology* 110:390–394
- Peltier RL, Emmett-Oglesby MW, Thomas WH, Schenk S (1994) Failure of ritanserin to block the discriminative stimulus or reinforcing effects of cocaine. *Pharmacol Biochem Behav* 48:473–478

- Pettit HO, Pan HT, Parsons LH, Justice JB, Jr (1990) Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. *J Neurochem* 55: 798–804
- Phelix CF, Broderick PA (1995) Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. *Brain Res Bull* 37:37–40
- Pineyro G, Montigny C, Blier P (1995) 5-HT-1D receptors regulate 5-HT release in the rat raphe nuclei: in vivo voltammetry and in vitro superfusion studies. *Neuropsychopharmacol* 13:249–260
- Pranzatelli MR, Razi P (1994) Drug-induced regulation of [¹²⁵I]iodocyanopindolol-labeled 5-hydroxytryptamine_{1b} receptor binding sites in the central nervous system. *Neuropsychopharmacology* 10:259–264
- Richardson NR, Roberts DCS (1991) Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration. *Life Sci* 49:833–840
- Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. *Science* 237:1219–1223
- Roberts DCS (1993) Self-administration of GBR 12909 on a fixed ratio and progressive ratio schedule in rats. *Psychopharmacology* 111:202–206
- Roberts DCS, Corcoran ME, Fibiger HC (1977) On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. *Pharmacol Biochem Behav* 6:615–620
- Roberts DCS, Koob GF, Klonoff P, Fibiger HC (1980) Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. *Pharmacol Biochem Behav* 12:781–787
- Rompré P-P, Baucó P (1990) GBR 12909 reverses the SCH 23390 inhibition of rewarding effects of brain stimulation. *Eur J Pharmacol* 182:181–184
- Rudnick G, Wall SC (1991) Binding of the cocaine analogue 2 beta-[³H] carboxymethoxy-3 beta-(4-fluorophenyl)tropane to the serotonin transporter. *Mol Pharmacol* 40:421–426
- Satel SL, Krystal JH, Delgado PL, Kosten TR, Charmey DS (1995) Tryptophan depletion and attenuation of cue-induced craving for cocaine. *Am J Psychiatry* 152:778–783
- Scearce K, Castanon N, Hen R (1995) Mice lacking 5-HT_{1b} receptors display altered behavioral responses to cocaine. *Soc Neurosci Abstr* 21:715
- Schoeffter P, Hoyer D (1989) Interactions of arylpiperazines with 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1C} and 5-HT_{1D} receptors: do discriminatory 5-HT_{1B} ligands exist? Naunyn-Schmiedeberg's *Arch Pharmacol* 339:675–683
- Speelman RD (1993) Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. *Psychopharmacology* 112:93–99
- Tricklebank MD, Middlemiss DN, Neill J (1986) Pharmacological analysis of the behavioral and thermoregulatory effects of the putative 5-HT₁ receptor agonist, RU 24969, in the rat. *Neuropharmacology* 8:877–886
- Van de Kar LD, Carnes M, Maslowski RJ, Bonadonna AM, Rittenhouse PA, Kunimoto K, Peichowski RA, Bethea CL (1989) Neuroendocrine evidence for denervation supersensitivity of serotonin receptors. Effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion. *J Pharmacol Exp Ther* 251:428–434
- Vergé D, Daval G, Marcinkiewicz M, Patey A, El Mestikawy S, Gozlan H, Hamon M (1986) Quantitative autoradiography of multiple 5-HT₁ receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. *J Neurosci* 6:4373–4382
- Weiss F, Parsons LH, Markou A (1995) Neurochemistry of cocaine withdrawal. In: Hammer RP Jr (ed) *The neurobiology of cocaine: cellular and molecular mechanisms*. CRC Press, Boca Raton New York London Tokyo, pp 163–180
- Weissmann D, Mach E, Oberlander C, Demasse Y, Pujol JF (1986) Evidence for hypersensitivity of 5-HT_{1b} binding sites in the substantia nigra of the rat after 5,7-dihydroxytryptamine intraventricular injection. *Neurochem Int* 9:191–200
- White FJ, Hu X-T, Henry DJ (1993) Electrophysiological effects of cocaine in the rat nucleus accumbens: microiontophoretic studies. *J Pharmacol Exp Ther* 266:1075–1084
- White FJ, Hu X-T, Henry DJ, Zhang X-F (1995) Neurophysiological alterations in the mesocorticolimbic dopamine system with repeated cocaine administration. In: Hammer RP Jr (ed) *The neurobiology of cocaine: cellular and molecular mechanisms*. CRC Press, Boca Raton New York London Tokyo, pp 99–120
- Winters TA, Slifer BL (1989) Discriminative stimulus properties of cocaine: is there mediation by serotonin? *FASEB J* 3:295
- Wise RA (1984) Neural mechanisms of the reinforcing action of cocaine. In: Grabowski J (ed) *Cocaine: pharmacology, effects, and treatment of abuse* (NIDA Research Monograph Series, vol. 50). United States Government Printing Office, pp 15–33
- Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. *Psychol Rev* 94:469–492
- Witkin JM, Nichols DE, Terry P, Katz JL (1991) Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. *J Pharmacol Exp Ther* 257:706–713
- Yadid G, Pacak K, Kopin IJ, Goldstein DS (1994) Endogenous serotonin stimulates striatal dopamine release in conscious rats. *J Pharmacol Exp Ther* 270:1158–1165